Methods of preventing sustained monomorphic ventricular tachycardia following myocardial ischemia, decreasing infarct size and/or decreasing the incidence and/or maximum intrinsic rate of very rapid ventricular triplets following myocardial ischemia is disclosed. The methods involve administering an effective amount of a composition that inhibits substantial loss of beta-adrenergic receptor kinase (.beta.-ARK) activity and/or .beta.-ARK expression.

 
Web www.patentalert.com

< Clinical indications for genotyping polymorphic variants of G-protein coupled receptors

> Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones

~ 00423